{"id":1299,"date":"2016-09-28T18:00:12","date_gmt":"2016-09-28T12:30:12","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1299"},"modified":"2023-06-16T11:00:41","modified_gmt":"2023-06-16T05:30:41","slug":"the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers","title":{"rendered":"Merck Focuses its Research on Hard to Treat Cancers"},"content":{"rendered":"<p style=\"text-align: justify;\">Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that are hard to treat. Keeping in view with this agenda, Merck has announced that the new research that has been conducted from their marketed and pipeline compounds will be presented at this year&#8217;s European Society for Medical Oncology annual meeting in Denmark. The presentations are to be focussed on hard-to-treat cancers, and will include results for Erbitux\u00ae (cetuximab) in metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN); preliminary study results in bladder cancer and renal cell carcinoma (RCC) for avelumab, which is being developed in collaboration with Pfizer; and updates on the Phase II program for tepotinib* in non-small cell lung cancer (NSCLC).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that are hard to treat. Keeping in view with this agenda, Merck has announced that the new research that has been conducted from their marketed and pipeline compounds will be presented at this [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1301,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[2063,1771,17344,17345,395,460,854],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-1299","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-bladder-cancer","tag-cancers","tag-esmo","tag-european-society-for-medical-oncology","tag-merck","tag-pfizer","tag-renal-cell-carcinoma","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Merck to shift its focus toward hard-to-treat cancers | Delveinsight<\/title>\n<meta name=\"description\" content=\"Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to shift its focus toward hard-to-treat cancers | Delveinsight\" \/>\n<meta property=\"og:description\" content=\"Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-09-28T12:30:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-16T05:30:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022645\/tumor-starting.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"466\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck to shift its focus toward hard-to-treat cancers | Delveinsight","description":"Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers","og_locale":"en_US","og_type":"article","og_title":"Merck to shift its focus toward hard-to-treat cancers | Delveinsight","og_description":"Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-09-28T12:30:12+00:00","article_modified_time":"2023-06-16T05:30:41+00:00","og_image":[{"width":700,"height":466,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022645\/tumor-starting.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers","url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers","name":"Merck to shift its focus toward hard-to-treat cancers | Delveinsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022645\/tumor-starting.jpg","datePublished":"2016-09-28T12:30:12+00:00","dateModified":"2023-06-16T05:30:41+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-merck-focuses-its-research-on-hard-to-treat-cancers#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022645\/tumor-starting.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022645\/tumor-starting.jpg","width":700,"height":466},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022645\/tumor-starting-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">bladder cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ESMO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">European Society For Medical Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Renal Cell Carcinoma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">bladder cancer<\/span>","<span class=\"advgb-post-tax-term\">cancers<\/span>","<span class=\"advgb-post-tax-term\">ESMO<\/span>","<span class=\"advgb-post-tax-term\">European Society For Medical Oncology<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Renal Cell Carcinoma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Sep 28, 2016","modified":"Updated on Jun 16, 2023"},"absolute_dates_time":{"created":"Posted on Sep 28, 2016 6:00 pm","modified":"Updated on Jun 16, 2023 11:00 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1299"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1299\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1301"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1299"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1299"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}